Are you living with overweight or obesity and do not have diabetes?
If so, you may be eligible to participate in a clinical research study evaluating a GLP-1 medicine (RO7795068) and an amylin analog (petrelintide) for weight management.
ABOUT THE STUDY
This is a Phase 2 study evaluating how RO7795068 and petrelintide affect body weight.
WHO MAY QUALIFY?
You may be eligible to participate if you meet all the following:
Age 18 years or older
Body mass index (BMI) of 27 or higher (classified as overweight or obesity)
Do not have diabetes
Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) within the past 6 months
Have never had surgery for treatment of obesity
INTERESTED IN LEARNING MORE?
Click below to complete a short questionnaire to see if you may be eligible.
Study Sponsor: Hoffmann-La Roche
ClinicalTrials.gov ID: NCT07589686 https://clinicaltrials.gov/study/NCT07589686